Inactivation of hypoxia-induced YAP by statins overcomes hypoxic resistance tosorafenib in hepatocellular carcinoma cells
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Inactivation of hypoxia-induced YAP by statins overcomes hypoxic resistance tosorafenib in hepatocellular carcinoma cells
Authors
Keywords
-
Journal
Scientific Reports
Volume 6, Issue 1, Pages -
Publisher
Springer Nature
Online
2016-08-01
DOI
10.1038/srep30483
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Nuclear translocation and activation of YAP by hypoxia contributes to the chemoresistance of SN38 in hepatocellular carcinoma cells
- (2016) Xiao-Yang Dai et al. Oncotarget
- An Imbalance in TAZ and YAP Expression in Hepatocellular Carcinoma Confers Cancer Stem Cell-like Behaviors Contributing to Disease Progression
- (2015) H. Hayashi et al. CANCER RESEARCH
- The sweet side of YAP/TAZ
- (2015) Giulia Santinon et al. CELL CYCLE
- YAP activates the Hippo pathway in a negative feedback loop
- (2015) Xiaoming Dai et al. CELL RESEARCH
- A YAP/TAZ-induced feedback mechanism regulates Hippo pathway homeostasis
- (2015) Toshiro Moroishi et al. GENES & DEVELOPMENT
- The Hippo pathway transcriptional co-activator, YAP, confers resistance to cisplatin in human oral squamous cell carcinoma
- (2015) KYOHEI YOSHIKAWA et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma
- (2015) Andrew X. Zhu et al. JOURNAL OF CLINICAL ONCOLOGY
- The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies
- (2015) Luping Lin et al. NATURE GENETICS
- Advances in targeted therapies for hepatocellular carcinoma in the genomic era
- (2015) Josep M. Llovet et al. Nature Reviews Clinical Oncology
- Sorafenib-based combined molecule targeting in treatment of hepatocellular carcinoma
- (2015) Jian-Jun Gao WORLD JOURNAL OF GASTROENTEROLOGY
- Hypoxia inducible factor in hepatocellular carcinoma: A therapeutic target
- (2015) Daniel Lin WORLD JOURNAL OF GASTROENTEROLOGY
- Focal Gains of VEGFA: Candidate Predictors of Sorafenib Response in Hepatocellular Carcinoma
- (2014) Josep M. Llovet CANCER CELL
- Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
- (2014) Rakesh K. Jain CANCER CELL
- YAP-Induced Resistance of Cancer Cells to Antitubulin Drugs Is Modulated by a Hippo-Independent Pathway
- (2014) Y. Zhao et al. CANCER RESEARCH
- Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells
- (2014) Dali Zhao et al. CELLULAR SIGNALLING
- The Hippo-YAP signaling pathway and contact inhibition of growth
- (2014) Barry M. Gumbiner et al. JOURNAL OF CELL SCIENCE
- YAP activation is an early event and a potential therapeutic target in liver cancer development
- (2014) Andrea Perra et al. JOURNAL OF HEPATOLOGY
- Hypoxia promotes 786-O cells invasiveness and resistance to sorafenib via HIF-2α/COX-2
- (2014) Chun-Xiong Zhao et al. MEDICAL ONCOLOGY
- Fbxw7 is an independent prognostic marker and induces apoptosis and growth arrest by regulating YAP abundance in hepatocellular carcinoma
- (2014) Kangsheng Tu et al. Molecular Cancer
- Metabolic control of YAP and TAZ by the mevalonate pathway
- (2014) Giovanni Sorrentino et al. NATURE CELL BIOLOGY
- Hypoxia regulates Hippo signalling through the SIAH2 ubiquitin E3 ligase
- (2014) Biao Ma et al. NATURE CELL BIOLOGY
- HCC—subtypes, stratification and sorafenib
- (2014) Gregory J. Gores Nature Reviews Gastroenterology & Hepatology
- YAP/TEAD Co-Activator Regulated Pluripotency and Chemoresistance in Ovarian Cancer Initiated Cells
- (2014) Yan Xia et al. PLoS One
- MEK1 promotes YAP and their interaction is critical for tumorigenesis in liver cancer
- (2013) Lanlan Li et al. FEBS LETTERS
- Hepatocellular carcinoma and sorafenib: too many resistance mechanisms?
- (2013) Carmen Berasain GUT
- Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma
- (2013) Yingjian Liang et al. HEPATOLOGY
- αB-crystallin complexes with 14-3-3ζ to induce epithelial-mesenchymal transition and resistance to sorafenib in hepatocellular carcinoma
- (2013) Xiao-Yong Huang et al. HEPATOLOGY
- Serum response factor induces epithelial to mesenchymal transition with resistance to sorafenib in hepatocellular carcinoma
- (2013) JUN SANG BAE et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- SurvExpress: An Online Biomarker Validation Tool and Database for Cancer Gene Expression Data Using Survival Analysis
- (2013) Raul Aguirre-Gamboa et al. PLoS One
- Interplay of mevalonate and Hippo pathways regulates RHAMM transcription via YAP to modulate breast cancer cell motility
- (2013) Z. Wang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- β-Catenin-Driven Cancers Require a YAP1 Transcriptional Complex for Survival and Tumorigenesis
- (2012) Joseph Rosenbluh et al. CELL
- An update on targeting Hippo-YAP signaling in liver cancer
- (2012) Angela M Liu et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib
- (2012) Zakaria Ezzoukhry et al. INTERNATIONAL JOURNAL OF CANCER
- Antiangiogenic Therapy for Primary Liver Cancer: Correlation of Changes in Dynamic Contrast-Enhanced Magnetic Resonance Imaging with Tissue Hypoxia Markers and Clinical Response
- (2011) Adam C. Yopp et al. ANNALS OF SURGICAL ONCOLOGY
- Connective tissue growth factor autocriny in human hepatocellular carcinoma: Oncogenic role and regulation by epidermal growth factor receptor/yes-associated protein-mediated activation
- (2011) Raquel Urtasun et al. HEPATOLOGY
- The Hippo-YAP pathway in organ size control and tumorigenesis: an updated version
- (2010) B. Zhao et al. GENES & DEVELOPMENT
- Gene expression in nontumoral liver tissue and recurrence-free survival in hepatitis C virus-positive hepatocellular carcinoma
- (2010) Masato Tsuchiya et al. Molecular Cancer
- Mst Out and HCC In
- (2009) Bin Zhao et al. CANCER CELL
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now